Research ArticleAccepted Article
Long-term drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis
Paul Emery, Bonnie Vlahos, Piotr Szczypa, Mazhar Thakur, Heather E. Jones, John Woolcott, Paul V. Santos Estrella, Catherine Rolland, Allan Gibofsky, Gustavo Citera, Sargunan Sockalingam and Lisa Marshall
The Journal of Rheumatology June 2019, jrheum.181398; DOI: https://doi.org/10.3899/jrheum.181398
Paul Emery
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds UK Funding: The systematic literature review to support this manuscript was sponsored by Pfizer. Disclosures: PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron; declares consultancy fees from AbbVie, Celgene, Merck & Company, and Pfizer; and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Company, Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of this manuscript. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. SS declares no conflict of interest. Address correspondence to: Dr Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK Email: p.emery@leeds.ac.uk
Bonnie Vlahos
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds UK Funding: The systematic literature review to support this manuscript was sponsored by Pfizer. Disclosures: PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron; declares consultancy fees from AbbVie, Celgene, Merck & Company, and Pfizer; and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Company, Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of this manuscript. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. SS declares no conflict of interest. Address correspondence to: Dr Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK Email: p.emery@leeds.ac.uk
Piotr Szczypa
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds UK Funding: The systematic literature review to support this manuscript was sponsored by Pfizer. Disclosures: PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron; declares consultancy fees from AbbVie, Celgene, Merck & Company, and Pfizer; and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Company, Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of this manuscript. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. SS declares no conflict of interest. Address correspondence to: Dr Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK Email: p.emery@leeds.ac.uk
Mazhar Thakur
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds UK Funding: The systematic literature review to support this manuscript was sponsored by Pfizer. Disclosures: PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron; declares consultancy fees from AbbVie, Celgene, Merck & Company, and Pfizer; and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Company, Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of this manuscript. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. SS declares no conflict of interest. Address correspondence to: Dr Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK Email: p.emery@leeds.ac.uk
Heather E. Jones
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds UK Funding: The systematic literature review to support this manuscript was sponsored by Pfizer. Disclosures: PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron; declares consultancy fees from AbbVie, Celgene, Merck & Company, and Pfizer; and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Company, Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of this manuscript. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. SS declares no conflict of interest. Address correspondence to: Dr Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK Email: p.emery@leeds.ac.uk
John Woolcott
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds UK Funding: The systematic literature review to support this manuscript was sponsored by Pfizer. Disclosures: PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron; declares consultancy fees from AbbVie, Celgene, Merck & Company, and Pfizer; and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Company, Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of this manuscript. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. SS declares no conflict of interest. Address correspondence to: Dr Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK Email: p.emery@leeds.ac.uk
Paul V. Santos Estrella
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds UK Funding: The systematic literature review to support this manuscript was sponsored by Pfizer. Disclosures: PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron; declares consultancy fees from AbbVie, Celgene, Merck & Company, and Pfizer; and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Company, Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of this manuscript. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. SS declares no conflict of interest. Address correspondence to: Dr Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK Email: p.emery@leeds.ac.uk
Catherine Rolland
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds UK Funding: The systematic literature review to support this manuscript was sponsored by Pfizer. Disclosures: PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron; declares consultancy fees from AbbVie, Celgene, Merck & Company, and Pfizer; and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Company, Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of this manuscript. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. SS declares no conflict of interest. Address correspondence to: Dr Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK Email: p.emery@leeds.ac.uk
Allan Gibofsky
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds UK Funding: The systematic literature review to support this manuscript was sponsored by Pfizer. Disclosures: PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron; declares consultancy fees from AbbVie, Celgene, Merck & Company, and Pfizer; and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Company, Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of this manuscript. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. SS declares no conflict of interest. Address correspondence to: Dr Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK Email: p.emery@leeds.ac.uk
Gustavo Citera
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds UK Funding: The systematic literature review to support this manuscript was sponsored by Pfizer. Disclosures: PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron; declares consultancy fees from AbbVie, Celgene, Merck & Company, and Pfizer; and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Company, Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of this manuscript. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. SS declares no conflict of interest. Address correspondence to: Dr Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK Email: p.emery@leeds.ac.uk
Sargunan Sockalingam
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds UK Funding: The systematic literature review to support this manuscript was sponsored by Pfizer. Disclosures: PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron; declares consultancy fees from AbbVie, Celgene, Merck & Company, and Pfizer; and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Company, Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of this manuscript. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. SS declares no conflict of interest. Address correspondence to: Dr Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK Email: p.emery@leeds.ac.uk
Lisa Marshall
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds UK Funding: The systematic literature review to support this manuscript was sponsored by Pfizer. Disclosures: PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron; declares consultancy fees from AbbVie, Celgene, Merck & Company, and Pfizer; and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Company, Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of this manuscript. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. SS declares no conflict of interest. Address correspondence to: Dr Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK Email: p.emery@leeds.ac.uk
Article Information
jrheum.181398
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online June 1, 2019.
Article Versions
- You are currently viewing a Latest version of this article (June 1, 2019 - 04:00).
- latest version (November 1, 2019 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2019 The Journal of Rheumatology
Author Information
- Paul Emery,
- Bonnie Vlahos,
- Piotr Szczypa,
- Mazhar Thakur,
- Heather E. Jones,
- John Woolcott,
- Paul V. Santos Estrella,
- Catherine Rolland,
- Allan Gibofsky,
- Gustavo Citera,
- Sargunan Sockalingam and
- Lisa Marshall
-
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds UK Funding: The systematic literature review to support this manuscript was sponsored by Pfizer. Disclosures: PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron; declares consultancy fees from AbbVie, Celgene, Merck & Company, and Pfizer; and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Company, Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of this manuscript. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. SS declares no conflict of interest.
Address correspondence to: Dr Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK Email: p.emery@leeds.ac.uk
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Long-term drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis
Paul Emery, Bonnie Vlahos, Piotr Szczypa, Mazhar Thakur, Heather E. Jones, John Woolcott, Paul V. Santos Estrella, Catherine Rolland, Allan Gibofsky, Gustavo Citera, Sargunan Sockalingam, Lisa Marshall
The Journal of Rheumatology Jun 2019, jrheum.181398; DOI: 10.3899/jrheum.181398
Accepted manuscript
Long-term drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis
Paul Emery, Bonnie Vlahos, Piotr Szczypa, Mazhar Thakur, Heather E. Jones, John Woolcott, Paul V. Santos Estrella, Catherine Rolland, Allan Gibofsky, Gustavo Citera, Sargunan Sockalingam, Lisa Marshall
The Journal of Rheumatology Jun 2019, jrheum.181398; DOI: 10.3899/jrheum.181398